Your email has been successfully added to our mailing list.

×
-0.0302432610124918 -0.0302432610124918 -0.0302432610124918 -0.0302432610124918 -0.0243261012491782 -0.0203813280736358 -0.0210387902695595 -0.0197238658777121
Stock impact report

Novartis buys Amblyotech to develop tech products for lazy eye [Reuters]

UBISOFT ENTMT UNSP/ADR (UBSFY) 
Company Research Source: Reuters
Novartis buys Amblyotech to develop tech products for lazy eye ZURICH (Reuters) - Novartis ( NOVN.S ) has bought U.S. software start-up Amblyotech, to develop digital technology to treat children and adults with lazy eye, the Swiss drugmaker said on Monday. Novartis said it would work with Ubisoft ( UBIP.PA ) and McGill University to treat the condition, also known as amblyopia, which can lead to vision loss and affects roughly 3% of the world’s population. Amblyotech uses active gaming and passive video technology with 3-D glasses, training the eyes to work together to view an image in full. Terms of the deal were not disclosed. Show less Read more
Impact Snapshot
Event Time:
UBSFY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
UBSFY alerts

from News Quantified
Opt-in for
UBSFY alerts

from News Quantified